文献速递乳腺US

三阴性乳腺癌患者新辅助全身治疗期间的腋窝超声检查

Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients.
PubMed 文献 · Eur J Radiol · 2020-07-10

本研究为正在进行的单机构临床试验的中期分析,纳入106例I-III期三阴性乳腺癌患者,评估新辅助全身治疗中期腋窝超声异常淋巴结数目与手术病理残留淋巴结病变的关系。结果显示,中期腋窝超声异常淋巴结>4枚与手术后淋巴结阳性显著相关(AUC=0.908,p<0.0001;PPV=90%)。作者认为,若后续分析证实,中期腋窝超声可用于识别不太可能达到淋巴结病理完全缓解、应接受替代治疗的患者。

要点

  • 中期腋窝超声异常淋巴结>4枚与手术后淋巴结阳性显著相关,AUC=0.908,PPV=90%。
  • 有残留淋巴结病变者中期异常淋巴结中位数为5枚(SD 5),无病变者为0枚(SD 2),p<0.0001。
  • 作者认为若后续分析证实,中期腋窝超声可识别不太可能达到淋巴结病理完全缓解的患者。

关键影像表现/征象

  • 治疗中期异常淋巴结中位数:有残留淋巴结病变者5枚(SD 5),无淋巴结病变者0枚(SD 2),p<0.0001。
  • 106例中26例(25%)手术时有残留淋巴结病变,80例(75%)无淋巴结病变。

诊断标准与关键数值

  • 中期腋窝超声异常淋巴结>4枚预测手术淋巴结阳性的AUC=0.908,p<0.0001,PPV=90%。

临床应用与阅片要点

  • 作者认为,若后续分析证实本研究结果,中期腋窝超声可用于识别不太可能达到淋巴结病理完全缓解、应接受替代治疗的患者。

局限性

  • 本研究为正在进行的单机构临床试验的中期分析。
  • 作者指出需后续分析证实其发现(若后续分析证实)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate the value of performing mid-treatment axillary ultrasound (AUS) in triple-negative breast cancer (TNBC) patients who are undergoing neoadjuvant systemic therapy (NAST) by determining the optimal cutoff number of abnormal nodes associated with residual nodal disease on surgical pathology.

MATERIALS AND METHODS: This sub-study, an interim analysis of an ongoing single-institution clinical trial enrolling patients with stage I-III TNBC, included 106 patients. Number of abnormal nodes at mid-treatment was assessed and recorded by experienced breast radiologists, who empirically categorized lymph nodes using a binary approach of sonographically-normal versus abnormal. Pathologic lymph node positivity was defined as presence of macrometastasis or micrometastasis in ≥1 axillary node from sentinel lymph node biopsy and/or axillary lymph node dissection.

RESULTS: Of 106 patients, 26 (25 %) had residual nodal disease and 80 (75 %) had no nodal disease at surgery. Median number of abnormal nodes at mid-treatment was 5 (standard deviation [SD], 5) for patients with residual nodal disease and 0 (SD, 2) for patients with no nodal disease at surgery (p < 0.0001). TNBC patients with >4 abnormal nodes at mid-treatment had a significantly higher chance of being node-positive at surgery (AUC = 0.908, p < 0.0001; PPV = 90 %).

CONCLUSION: Our data suggest that a cutoff of >4 abnormal nodes on mid-treatment AUS is associated with residual disease post-NAST. If our findings are substantiated by subsequent analyses, then mid-treatment AUS could be used to identify patients unlikely to achieve nodal pathologic complete response and who should be offered alternative therapy.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Candelaria RP, Adrada BE, Hess K, et al. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol. 2020. PMID: 32777736. doi:10.1016/j.ejrad.2020.109170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。